Enveric Biosciences Inc. (NASDAQ:ENVB) reported favorable outcomes from IND-enabling laboratory studies evaluating its primary drug candidate, EB-003. “These results represent an important milestone in the development of EB-003, provide additional support for its preclinical development profile, and support its continued advancement toward a planned first-in-human clinical trial,” said Joseph Tucker, Director and CEO of Enveric.

Ibogaine’s anecdotal and clinical signals on cravings, withdrawal, and even PTSD are growing, but the biggest obstacle is that ibogaine itself carries serious cardiac risk (QT prolongation, arrhythmias) and can produce an intense psychedelic experience lasting 10 hours or more, which would necessitate prolonged medical supervision in a clinical setting.

The Psychedelic Drugs resource page added to the FDA website might be yet another indicator that the regulator is increasingly interested in the field’s potential. In publishing this resource page, which sits alongside one dedicated to drug repurposing, the agency has coalesced July’s finalized guidance for the field and April’s executive order as well as […]

Radar previously reported that Moore may have achieved “smooth contour of the upper face” with the help of fat grafting or maybe even a brow lift. “She likely had a brow or forehead lift and fat grafting of the temple area to achieve a smooth contour of the upper face,” plastic surgeon Dr. Tia Liu […]

As clinical research advances beyond first-generation compounds, scientists are rethinking what psychedelic-inspired therapies could look like and how they may reshape the future of mental healthcare. For decades, psychedelic compounds occupied the fringes of medical research. Today, they’re at the center of one of the most active areas of neuroscience. From psilocybin and LSD to […]

Enveric’s lead candidate, EB-003, is a novel neuroplastogen that engages both the 5-HT2A and 5-HT1B receptors, a dual mechanism that may define a new class of neuropsychiatric treatments. This pharmacological profile is designed to promote adaptive rewiring of brain circuits while stabilizing emotional and behavioral regulation, potentially enabling durable recovery in patients with post-traumatic stress disorder (PTSD), treatment-resistant […]

A conversation with Joseph Tucker, Ph.D., CEO, Enveric Biosciences. The White House recently issued an executive order accelerating the use of psychedelics, such as psilocybin, MDMA, and ibogaine, in research and clinical trials. This order, however, does not change the current legal status of any of them.

Enveric Biosciences Inc. (NASDAQ:ENVB) on Tuesday highlighted preclinical findings for its lead candidate EB-003. It pointed to rapid reductions in PTSD-related fear responses, as recent federal policy signals growing support for psychedelic-based mental health treatments.

The White House recently issued an executive order accelerating the use of psychedelics, such as psilocybin, MDMA, and ibogaine, in research and clinical trials. This order, however, does not change the current legal status of any of them.

The U.S. FDA has fast-tracked the review of three psychedelic drugs being developed to treat depression, PTSD, and other mental health conditions. CGTN’s Sean Callebs spoke with Dr. Robert Discordia, Co-Founder and CEO of Equulus Therapeutics, about the science, the politics, and what accelerated approval could mean for patients.